Switching from Humira to Tremfya in Ulcerative Colitis
When switching from adalimumab (Humira) to guselkumab (Tremfya) in moderate-to-severe ulcerative colitis, patients typically experience minimal transition symptoms, and you should start Tremfya immediately when the next Humira dose is due without any washout period.
Expected Patient Experience During Switch
Patients generally do not experience specific "switching symptoms" when transitioning between biologics. The main concern is disease flare if there's a gap in therapy. Most patients maintain their current disease state or gradually improve once Tremfya takes effect.
Timeline of What to Expect:
- Weeks 0-4: Disease activity may remain stable or slightly worsen if Humira effect is waning
- Weeks 4-12: Gradual improvement in symptoms (reduced stool frequency, less blood, decreased urgency)
- Week 12 onwards: Peak therapeutic effect, with potential for clinical remission
Transition Protocol
Step 1: Timing the Switch
Start Tremfya on the day your next Humira dose would be due 1. Since Humira for UC is dosed at 40 mg every other week after induction, you simply replace that dose with the first Tremfya infusion.
- No washout period needed
- No overlap dosing required
- Immediate transition minimizes risk of disease flare
Step 2: Tremfya Dosing Schedule
Induction Phase:
- Week 0: 200 mg IV infusion
- Week 4: 200 mg IV infusion
- Week 8: 200 mg IV infusion
Maintenance Phase (starting Week 12):
- 200 mg subcutaneous every 4 weeks OR
- 100 mg subcutaneous every 8 weeks
The every-4-week dosing may be preferred initially given your prior adalimumab failure 2.
Step 3: Concurrent Medications
- Continue aminosalicylates if currently taking (though can consider stopping per AGA guidelines) 2
- Continue corticosteroids if on them, with plan to taper once Tremfya shows effect
- Avoid adding immunomodulators (azathioprine, 6-MP) - no evidence supports combining IL-23 inhibitors with immunomodulators 2
Rationale for This Approach
Guselkumab is classified as intermediate efficacy in biologic-exposed patients (specifically TNF-exposed like you), making it a reasonable next-line option 2. In the QUASAR trials, guselkumab demonstrated:
- Clinical remission rates of 16-24% at Week 12 in induction 3
- Clinical remission rates of 37-46% at Week 44 in maintenance 3
- Efficacy in both biologic-naïve and biologic-experienced populations 4, 5
The 2024 AGA guidelines recommend guselkumab over no treatment (strong recommendation) and position it as intermediate efficacy after TNF failure 2.
Monitoring During Transition
Clinical Monitoring:
- Week 4: Assess symptom improvement (stool frequency, rectal bleeding)
- Week 12: Evaluate for clinical response - if no improvement, consider switching to higher efficacy agent (upadacitinib, tofacitinib, ustekinumab) 2
- Ongoing: Monitor for infections, injection site reactions
Laboratory Monitoring:
- Fecal calprotectin at baseline and Week 12
- CBC, CMP at baseline and periodically
- TB testing before initiation 2
Key Advantages of This Switch
- No washout needed: Immediate transition prevents disease flare
- Favorable safety profile: Lower infection risk compared to TNF antagonists 2
- Dual mechanism: Targets IL-23 production at CD64+ cells and neutralizes circulating IL-23 5
- Flexible maintenance dosing: Can adjust between q4w and q8w based on response
Important Caveats
- If you're over 65, a smoker, or have cardiovascular risk factors, guselkumab is preferred over JAK inhibitors (which would otherwise be higher efficacy) 2
- If planning pregnancy, guselkumab is safer than JAK inhibitors or S1P modulators 2
- If no response by Week 12-16, strongly consider switching to a higher efficacy agent rather than continuing 2, 6
The evidence shows switching within IL-23 inhibitor class can work (e.g., risankizumab to guselkumab in Crohn's showed 80% clinical response) 7, suggesting the class maintains efficacy even after prior biologic exposure.